Introduction to cardio-oncology: Anthracyclines induced cardiotoxicity

Authors

  • Chonthicha Tanking Cardiovascular unit, Chulabhorn hospital, Chulabhorn Royal Academy

Keywords:

Cardio-oncology, Chemotherapy induced cardiotoxicity, Anthracycline

Abstract

Cancer is known to be the leading cause of death among Thai people. New advanced technology has brought about many novel effective treatments which lead to an impressive increase in cancer survivors over the past decade. Parallelly, the number of morbidity and mortality due to treatment side effects also grows. Cardiovascular diseases are one of the most frequent side effects. Evidence founds that cancer treatment with chemotherapy has an adverse impact on the cardiovascular system. This article will discuss the burden, risk factors, and how to recognize and prevent chemotherapy induce cardiotoxicity especially from Anthracyclines. Since Anthracycline is highly used in treating cancer and is notorious for causing cardiotoxicity.

References

Boer RA, Meijers WC, Meer P, Veldhuisen DJ. Cancer and heart disease: associations and relations. Eur J Heart Fail. 2019;21(12):1515-1525. https://doi.org/10.1002/ejhf.1539

Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Eur Heart J. 2016;37(36):2768-2801. https://doi.org/10.1093/eurheartj/ehw211

Komuro I. Harmonization of Cardiovascular and Oncology and the Blossoming of Cardio-Oncology in Japan. https://doi.org/10.1016/j.jaccao.2020.11.011

Lenneman CG, Sawyer DB. Cardio-oncology: An update on cardiotoxicity of cancer-related treatment. Circ Res. 2016;118(6):1008-1020. https://doi.org/10.1161/CIRCRESAHA.115.303633

Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic Health Conditions in Adult Survivors of Childhood Cancer. N Engl J Med. 2006;355(15):1572-1582. https://doi.org/10.1056/nejmsa060185

Limat S, Daguindau E, Cahn J-Y, et al. Incidence and risk-factors of CHOP/R-CHOP-related cardiotoxicity in patients with aggressive non-Hodgkin’s lymphoma. J Clin Pharm Ther. 2014;39(2):168-174. https://doi.org/10.1111/jcpt.12124

Hall PS, Harshman LC, Srinivas S, Witteles RM. The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients. JACC Heart Fail. 2013;1(1):72-78. https://doi.org/10.1016/j.jchf.2012.09.001

Swain SM, Whaley FS, Gerber MC, et al. Cardioprotection With Dexrazoxane for Doxorubicin-Containing Therapy in Advanced Breast Cancer. Vol 15.; 1997.

Cardinale D, Colombo A, Bacchiani G, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015;131(22):1981-1988. https://doi.org/10.1161/CIRCULATIONAHA.114.013777

Plana JC, Galderisi M, Barac A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: A report from the American society of echocardiography and the European association of cardiovascular imaging. J Am Soc Echocardiogr. 2014;27(9):911-939. https://doi.org/10.1016/j.echo.2014.07.012

Downloads

Published

2021-04-16

How to Cite

1.
Tanking C. Introduction to cardio-oncology: Anthracyclines induced cardiotoxicity. J Chulabhorn Royal Acad [Internet]. 2021 Apr. 16 [cited 2024 May 24];3(2):71-9. Available from: https://he02.tci-thaijo.org/index.php/jcra/article/view/248592

Issue

Section

Academic Articles